By Sahil Pandey and Puyaan Singh Feb 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes ...
The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing ...
BridgeBio Pharma (BBIO) stock jumps as a Phase 3 trial for the company's achondroplasia therapy succeeds. Read more here.
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -The U.S. Food and Drug Administration on Tuesday extended its review of Ascendis Pharma's therapy for children with ...
Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...
The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pedia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results